5-HT2受体阻滞剂利培酮治疗脑卒中后精神障碍有效性及安全性的Meta分析  

Efficacy and safety of 5-HT2 receptor blocker of risperidone in the treatment of post-stroke dysphreniac:a Meta-analysis

作　　者：赵艳华 杨兴旺 ZHAO Yanhua;YANG Xingwang(Peking University First Hospital Taiyuan Hospital/Taiyuan Central Hospital,Taiyuan 030009,China;不详)

机构地区：[1]北京大学第一医院太原医院/太原市中心医院,太原市030009 [2]山西省中西医结合医院,太原市030013

出　　处：《临床合理用药》2025年第6期5-9,共5页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的基于Meta分析评价5-HT2受体阻滞剂利培酮治疗脑卒中后精神障碍的有效性及安全性。方法计算机检索万方数据知识服务平台、维普网、中国知网、中国生物医学文献服务系统与PubMed、Embase、Cochrane Library数据库,收集关于“5-HT2受体阻滞剂、利培酮、脑卒中后精神障碍”相关文献,检索时间为建库至2023年12月19日。采用循证医学方法进行统计,评价脑卒中后精神障碍患者对5-HT2受体阻滞剂利培酮反应性及耐受性。由研究人员对收集的文献进行筛选、资料提取,并使用RevMan 5.3软件进行Meta分析。结果最终纳入10篇符合标准的文献,共包含患者897例,其中试验组449例,对照组448例。Meta分析结果显示,试验组治疗有效性高于对照组,差异有统计学意义[OR=1.35,95%CI(1.03,1.78),Z=2.17,P=0.03];试验组与对照组不良反应睡眠障碍的发生率比较,差异无统计学意义[OR=1.00,95%CI(0.60,1.67),Z=0.01,P=0.99]。结论脑卒中后精神障碍患者对5-HT2受体阻滞剂利培酮反应性高,并且睡眠障碍耐受性高。Objective To evaluate the efficacy and safety of 5-HT2 receptor blocker of risperidone in the treatment of post-stroke dysphreniac based on Meta-analysis.Methods The relevant literature on"5-HT2 receptor blocker,risperidone,and post-stroke dysphreniac"was collected by computer search of Wanfang Data,VIP,CNKI,China Biomedical Literature Service System,PubMed,Embase and Cochrane Library databases,and the search time was from the establishment of the database to December 19,2023.Evidence-based medical methods were used to evaluate the response and tolerability of 5-HT2 receptor blocker of risperidone in patients with post-stroke dysphreniac.The collected studies were screened and extracted by the researchers,and RevMan 5.3 software was used for Meta-analysis.Results Ten articles that met the criteria were included,including 897 patients,a total of 449 cases in the experimental group and 448 cases in the control group.The results of Meta-analysis showed that,the effective rate of treatment of the experimental group was higher than that of the control group,and the difference was statistically significant[OR=1.35,95%CI(1.03,1.78),Z=2.17,P=0.03].There was no significant difference in the incidence of adverse reactions of sleep disorder between the experimental group and the control group[OR=1.00,95%CI(0.60,1.67),Z=0.01,P=0.99].Conclusion Patients with post-stroke psychiatric dysphreniac are highly responsive to 5-HT2 receptor blocker of risperidone and highly tolerate sleep disturbances.

关 键 词：脑卒中后 精神障碍 5-HT2受体阻滞剂 利培酮 META分析 

分 类 号：R74[医药卫生—神经病学与精神病学]